Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    NCT01525446
Previous Study | Return to List | Next Study

Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

This study has been terminated.
(Slow accrual)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Henning Willers, M.D., Massachusetts General Hospital Identifier:
First received: July 19, 2011
Last updated: February 12, 2016
Last verified: February 2016

Stereotactic body radiation therapy (SBRT) is a special form of treatment which pinpoints high doses of radiation directly to cancer. Standard radiation (or photon radiation) is commonly used for SBRT to treat Non-Small Cell Lung Cancer (NSCLC). Proton beam radiation is a special type of radiation only available at a few institutions in the US and has not been previously used in SBRT to treat NSCLC. The use of protons for SBRT may improve the accuracy of the treatment and may help to minimize the dose delivered unnecessarily to healthy tissue.

In this study, the investigators are evaluating the safety and effectiveness of proton-based SBRT for early-stage NSCLC located in the periphery of the lung.

Condition Intervention Phase
Non-small Cell Lung Cancer
Radiation: SBRT with proton beam radiation
Early Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Proton Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable, Peripheral Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Pilot Study

Resource links provided by NLM:

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Feasibility and safety [ Time Frame: 2 years ]
    To establish the feasibility and safety of fiducials placement by electromagnetic navigational bronchoscopy (ENB)

  • Safety and tolerability [ Time Frame: 2 years ]
    Frequency of radiation pneumonitis in participants treated with proton radiation

Secondary Outcome Measures:
  • Toxicity [ Time Frame: 2 years ]
    Describe the acute and late toxicities of treatment using CTCAE v4.0

  • Efficacy [ Time Frame: 2 years ]
    To describe radiological tumor responses

  • Disease Free survival [ Time Frame: 2 years ]
    To calculate local, regional, and distant failure rates

  • Overall survival [ Time Frame: 2 years ]
    To calculate the overall survival rate

Enrollment: 7
Study Start Date: September 2011
Study Completion Date: December 2015
Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SBRT with proton beam radiation
4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
Radiation: SBRT with proton beam radiation
4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)

Detailed Description:

Subjects will undergo an electronic navigational bronchoscopy (ENB) during which three markers will be placed around their tumor which will guide the delivery of proton beam radiation to their with more precision and accuracy.

Subjects will receive a CT scan to obtain images to plan radiation treatment. Proton radiation will be delivered daily (4 or 5 consecutive days) on an outpatient basis at Massachusetts General Hospital.

After the final dose of proton radiation subjects will be followed for 5 years. Subjects will be asked to return at 3 months, and then every 3 months until 2 years, and then every 6 months until 5 years. Subjects will receive a chest CT, tumor assessment by CT or PET, chest x-ray, pulmonary function tests and a physical exam.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed non-small cell lung cancer (need not be newly diagnosed)
  • Stage clinical T1 N0 M0 or T2 N0 M0
  • NSCLC must be limited to a single lesion
  • NSCLC must be peripherally located (> 2 cm from proximal bronchial tree and > 1 cm from mediastinal pleura)
  • NSCLC must be considered medically inoperable
  • Life expectancy greater than 6 months

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Prior radiation therapy to the lungs or mediastinum
  • Prior malignancy in the last 2 years unless treated definitively and disease free or carcinoma in situ or early stage skin cancers that have been definitively treated
  • Receiving other study agents or other types of cancer therapy
  • Uncontrolled intercurrent illness
  • Pacemaker or defibrillator-dependent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01525446

United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02214
Sponsors and Collaborators
Massachusetts General Hospital
National Cancer Institute (NCI)
Principal Investigator: Henning Willers, M.D. Massachusetts General Hospital
  More Information

Responsible Party: Henning Willers, M.D., Attending Radiation Oncologist, Massachusetts General Hospital Identifier: NCT01525446     History of Changes
Other Study ID Numbers: 11-021
Study First Received: July 19, 2011
Last Updated: February 12, 2016

Keywords provided by Massachusetts General Hospital:
Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms processed this record on May 22, 2017